Initial choice and switching of P2Y12 inhibitors among patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI)

被引：0
|
作者：
Wang, Yehua [1 ]
Brown, Joshua [2 ]
Cavallari, Larisa [3 ]
Winterstein, Almut [1 ]
机构：
[1] Univ Florida, Gainesville, FL 32611 USA
[2] Univ Florida, Coll Pharm, Ctr Drug Evaluat & Safety, Dept Pharmaceut Outcomes & Policy, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
386
引用
下载
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [1] Choice of P2Y12 Inhibitors After Acute Coronary Syndrome
    Ando, Giuseppe
    Gragnano, Felice
    Pelliccia, Francesco
    Calabro, Paolo
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 211 : 377 - 377
  • [2] ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI)
    Wang, Y.
    Cavallari, L.
    Brown, J.
    Cameron, T.
    Winterstein, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S16 - S16
  • [3] ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI)
    Wang, Y.
    Cavallari, L.
    Brown, J.
    Cameron, T.
    Winterstein, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S6 - S6
  • [4] Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
    Tantry, Udaya S.
    Navarese, Eliano P.
    Myat, Aung
    Gurbel, Paul A.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 60 (4-5) : 460 - 470
  • [5] COMPARATIVE SAFETY ASSESSMENT OF P2Y12 INHIBITORS FOR SECONDARY PROPHYLAXIS IN ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION
    Kumar, A.
    Lutsey, P. L.
    St Peter, W. L.
    Schommer, J. C.
    Van't Hof, J. R.
    Rajpurohit, A.
    Farley, J. F.
    VALUE IN HEALTH, 2022, 25 (07) : S311 - S311
  • [6] Adherence to P2Y12 inhibitors in acute coronary syndrome after a percutaneous coronary intervention: what can we improve?
    Han, Yaling
    Li, Yang
    EUROPEAN HEART JOURNAL, 2022, 43 (24) : 2314 - 2316
  • [7] P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes
    Alexopoulos, Dimitrios
    Varlamos, Charalampos
    Mpahara, Aikaterini
    Lianos, Ioannis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (10) : 717 - 727
  • [8] Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
    Kumar, Arun
    Lutsey, Pamela L.
    St. Peter, Wendy L.
    Schommer, Jon C.
    Van't Hof, Jeremy R.
    Rajpurohit, Abhijeet
    Farley, Joel F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (02) : 412 - 422
  • [9] P2Y12 INHIBITOR ADHERENCE TRAJECTORIES IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Turgeon, Ricky D.
    Koshman, Sheri
    Dong, Yuan
    Graham, Michelle
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 16 - 16
  • [10] Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization
    Kudaravalli, Mrudula
    Althouse, Andrew D.
    Marroquin, Oscar C.
    Khandhar, Sameer J.
    Sharbaugh, Michael S.
    Toma, Catalin
    Smith, A. J. Conrad
    Schindler, John T.
    Lee, Joon S.
    Mulukutla, Suresh R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 854 - 859
12345